FDA approves cancer treatment for tumors with specific biomarker

On May 23, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for the treatment of unresectable or metastatic solid tumors with the biomarker microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here